Clinical trial
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant…
NCT00005617 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005617 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma |
| Official title | A Phase I Trial Testing Mart-1 Peptide Immunization in Malignant Melanoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological, Procedure |
| Interventions | dendritic cell-MART-1 peptide vaccine, leukapheresis |
| Start date | Jul 1, 1997 |
| Primary completion | Jun 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: